Barclays
HCAT icon

Barclays’s Health Catalyst HCAT Stock Holding History

Barclays’s Portfolio HCAT Stock Details HCAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$124K Sell
71,627
-27,024
-27% -$51.6K ﹤0.01% 4214
2026
Q2 		$196K Buy
98,651
+32,512
+49% +$46.9K ﹤0.01% 3727
2026
Q1 		$84K Sell
66,139
-82,047
-55% -$154K ﹤0.01% 4099
2025
Q4 		$354K Buy
148,186
+10,100
+7% +$27.6K ﹤0.01% 4047
2025
Q3 		$394K Sell
138,086
-17,915
-11% -$61.3K ﹤0.01% 3952
2025
Q2 		$588K Sell
156,001
-109,352
-41% -$430K ﹤0.01% 3669
2025
Q1 		$1.2M Buy
265,353
+90,546
+52% +$479K ﹤0.01% 2998
2024
Q4 		$1.24M Buy
174,807
+14,656
+9% +$117K ﹤0.01% 3232
2024
Q3 		$1.3M Buy
160,151
+56,369
+54% +$407K ﹤0.01% 3177
2024
Q2 		$663K Sell
103,782
-721
-0.7% -$4.63K ﹤0.01% 2855
2024
Q1 		$787K Sell
104,503
-23,522
-18% -$215K ﹤0.01% 3303
2023
Q4 		$1.19M Buy
128,025
+74,816
+141% +$611K ﹤0.01% 3310
2023
Q3 		$538K Buy
53,209
+30,580
+135% +$365K ﹤0.01% 2760
2023
Q2 		$283K Sell
22,629
-6,570
-23% -$78.2K ﹤0.01% 3080
2023
Q1 		$341K Buy
29,199
+12,729
+77% +$162K ﹤0.01% 3511
2022
Q4 		$175K Buy
16,470
+12,054
+273% +$116K ﹤0.01% 3911
2022
Q3 		$43K Sell
4,416
-20,071
-82% -$266K ﹤0.01% 3823
2022
Q2 		$354K Buy
24,487
+4,582
+23% +$78.1K ﹤0.01% 3093
2022
Q1 		$521K Buy
+19,905
New +$565K ﹤0.01% 2874

Other funds holding HCAT

Nepsis Inc
Nepsis Inc Minneapolis, Minnesota $317M AUM 37.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
PGCM
Prescott Group Capital Management Tulsa, Oklahoma $1.11B AUM 20.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
71 West Capital Partners
71 West Capital Partners Boston, Massachusetts $3.06B AUM 23.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Williams & Novak
Williams & Novak Westlake Village, California $169M AUM 17.63% 1-Year Est. Return

Barclays's HCAT Position: Q3 2026 in Review

Barclays reduced its Health Catalyst (HCAT) stake by 27% in Q3 2026, selling an estimated $51.6K and leaving 71,627 shares worth $124K. The position accounts for ﹤0.01% of the portfolio, ranked #4214.

Barclays first reported a position in HCAT in Q1 2022 and has held it in 19 quarters since. The position peaked at $1.3M in Q3 2024. 44 funds tracked by Wall St. Rank hold HCAT as of Q3 2026.

  • Barclays held 71,627 shares of Health Catalyst worth $124K as of Q3 2026.
  • Barclays sold 27,024 Health Catalyst shares in Q3 2026, an estimated $51.6K.
  • Health Catalyst made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4214 holding.
  • Barclays first reported a position in Health Catalyst in Q1 2022 and has held it in 19 quarters since.
  • Barclays's Health Catalyst position peaked at $1.3M in Q3 2024.
  • 44 funds tracked by Wall St. Rank held Health Catalyst as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.